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excess of diabetes with statin therapy4). 
In a meta-analysis of 26 masked trials 
(including STOMP, CORONA, OCS, 
and HPS) with an average treatment 
duration of 3 years,8 muscle problems 
were reported by 14 000 patients but 
there was little difference between the 
treatment groups: 12·7% of participants 
assigned statin versus 12·4% of those 
assigned placebo; an absolute excess of 
0·3% (95% CI 0–0·7; p=0·06). Thompson 
asserts that we concluded that “statin 
myalgia does not exist”, but we did not. 
Instead, we concluded that the annual 
excess of muscle-related problems 
actually caused by (rather than being 
attributed to) statin therapy is no more 
than about 10–20 cases per 10 000 
treated individuals, with only about 
one of those cases associated with 
substantial elevations in creatine kinase 
concentrations (ie, myopathy) and 
requiring statin therapy to be stopped.
We are in agreement with 
Fabrice Bonnet and colleagues that the 
availability of additional large-scale 
evidence about the effects of statin 
therapy from randomised controlled 
trials in people aged over 75 years 
would be of value. However, as is 
discussed in our Review, the inverse 
associations of cholesterol with 
mortality in observational studies in 
older people appear to reflect a failure 
to take account of reverse causality 
(which becomes increasingly important 
with age as more people experience 
chronic disease). By contrast, Mendelian 
randomisation studies indicate that 
the strength of the association of LDL 
cholesterol with coronary heart disease 
continues unchanged into older ages.11 
Consequently, until additional evidence 
becomes available, it remains reasonable 
to extrapolate from the evidence among 
younger individuals to the use of statin 
therapy in people older than 75 years.4,12
With regard to the comments by 
Abramson and colleagues, the many 
misrepresentations of the evidence 
in their previous paper (including the 
claim, subsequently withdrawn, that 
statins cause side-effects in one-fifth 
of treated patients2,3) are dealt with in 
to press patients experiencing adverse 
effects from statins to comply”. We 
agree; however, it is also important that 
patients are not encouraged to stop 
statin therapy if they experience adverse 
events that are not actually caused by 
the statin.
The STOMP trial5 involved multiple 
comparisons of several different 
muscle-related measures: there were 
no apparent effects of statin therapy on 
muscle strength or endurance, aerobic 
performance, or physical activity, and, 
whether emphasis is put on the on-
treatment analysis reported by the 
investigators5 or on our intention-to-
treat analysis based on all randomly 
assigned patients,4 the observed 
difference in the muscle pain outcome 
remains compatible with chance. The 
assertion by Paul Thompson and Beth 
Taylor that the “p value exceeds the 
magical 0·05 of significance, but it is 
very close to this statistical threshold” 
represents a misunderstanding of 
the meaning of p values.6 Moreover, 
rather than single out one particular 
result in one particular study, it is more 
appropriate to base judgments on the 
totality of the evidence.
Thompson and Taylor state that 
only one randomised trial (CORONA,7 
of 5011 elderly patients with heart 
failure) included in their meta-analysis8 
specifically sought information about 
muscle symptoms. However, this is 
incorrect: patients were also asked 
about such symptoms at each follow-up 
visit in (at least) the Oxford Cholesterol 
Study (OCS)9 and the Heart Protection 
Study (HPS),10 which involved more 
patients (621 and 20 536, respectively) 
and longer treatment exposure 
(3·4 and 5·3 years, respectively) than 
STOMP (468 patients for 6 months5). 
Consequently, the trial that Thompson 
and colleagues propose has already been 
done in large numbers of people with 
comorbidities.
Moreover, as discussed in our Review, 
randomised masked trials are able 
to detect differences that exist in the 
incidence of adverse events even if they 
are not sought specifically (eg, the small 
Collins and colleagues should perform 
a larger STOMP-like RCT to make sure 
they are right before concluding that 
statin myalgia does not exist.
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The comments by Simon Dimmitt 
and colleagues have already been 
addressed in a response to a previous 
letter from them.1 In particular, lowering 
LDL cholesterol more intensively with 
higher-dose statin therapy has been 
shown to produce larger reductions 
in vascular events than with smaller 
LDL reductions. With respect to 
the suggestion that adverse effects 
contribute to more than half of patients 
discontinuing statin therapy, results 
from randomised masked trials have 
shown that patients are no more 
likely to discontinue statin therapy 
than placebo; that is, Dimmitt and 
colleagues confuse attribution with 
causation (as did John Abramson and 
colleagues2,3). Moreover, as is discussed 
in our Review,4 many of these trials 
were started before statin therapy was 
being widely used, so few of the patients 
would have been previously exposed to 
a statin and excluded because of having 
had problems with it. Dimmitt and 
colleagues state that it is “unreasonable 
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regimens (without good evidence of 
higher rates of side-effects other than 
myopathy).
Consequently, it is appropriate to 
base the estimated magnitude of 
benefit that can be achieved by the 
use of an effective statin regimen 
on the LDL reduction that is likely 
to be achieved (rather than on the 
risk reduction per mmol/L): that is, 
lowering LDL cholesterol by 2 mmol/L 
for 5 years in 10 000 patients would 
typically prevent one (or more) 
major vascular event from occurring 
in about 1000 patients (ie, 10% 
absolute benefit) with pre-existing 
occlusive vascular disease (secondary 
prevention) and in 500 patients 
(ie, 5% absolute benefit) who are at 
increased risk but have not yet had a 
vascular event (primary prevention). 
Figure 5 provided estimates for 
the absolute benefits that would 
be achieved with different LDL 
reductions.4 However, because statin 
therapy reduces vascular disease risk 
during each year that it continues to 
be taken, the absolute benefits would 
be even larger with more prolonged 
therapy. 
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detail in our Review. We also explained 
that analyses based on a composite 
outcome for which the direction and 
magnitude of the effects of treatment 
on the separate components are similar 
(as is the case with statin therapy 
and major vascular events) can allow 
reliable evidence to emerge about 
the effects in different circumstances, 
because they are based on much larger 
numbers of events than for any of the 
separate components. So, for example, 
combination of the beneficial effect 
of statin therapy on vascular mortality 
overall and the definite reduction in 
major vascular events among lower-
risk patients provides support for 
concluding that statin therapy reduces 
the risk of death among lower-risk 
patients (despite the absence of a 
significant reduction in the relatively 
small number of deaths among such 
individuals considered in isolation).
As was discussed in our Review, the 
use of such composite outcomes does 
not mean that equal weight should 
necessarily be given to the different 
components of the composite in 
deciding whether or not to use the 
treatment. However, nor should effects 
on some types of major vascular events 
be dismissed entirely, as Abramson and 
colleagues seek to do, when they are 
associated with subsequent morbidity 
and mortality.
Additionally, it is a mistake not to 
recognise that intention-to-treat 
analyses tend to under estimate the 
effects of actually taking a treatment. 
Table 3 in our Review4 indicates that 
actual use of an effective statin regimen 
(eg, atorvastatin 40 mg daily) would 
reduce LDL cholesterol by at least 
2 mmol/L in individuals who present 
with concentrations of 4 mmol/L or 
more (estimated to be about half of the 
European or North American population 
in the absence of statin therapy). As 
shown in figure 3,4 the reductions in 
the risks of major vascular events were 
larger in trials in which there were larger 
reductions in LDL cholesterol, and 
more intensive statin therapy produced 
larger reductions in risk than lower dose 
Lessons from the 
controversy over statins
Jane Armitage and colleagues, 
led by senior author Rory Collins, 
(Nov 5, p 2237)1 and Richard Horton 
(Nov 5, p 2237)2 appear to believe that 
retraction of an article from The BMJ 
will end the debate about statins and 
primary prevention. Even were there 
grounds for retraction, I fear they 
would be disappointed. Questions 
about the evidence base for statins 
continue to emerge from many 
quarters: how strong is the evidence, 
how large is the benefit for individuals 
at lowest risk of heart disease, how well 
did the trials record common minor 
side-effects, how representative were 
the trials of women and the elderly, 
For questions about the 
evidence base for statins see 
http://blogs.bmj.com/
bmj/2016/09/12/richard-
lehman-where-next-with-
statins/
